MannKind | MNKD - Equity Capital And Reserves


MannKind reported $-44.55M in Equity Capital and Reserves for its fiscal quarter ending in September of 2025.





Equity Capital And Reserves Change Date
Adma Biologics USD 431.19M 32.87M Sep/2025
BioCryst Pharmaceuticals USD -387.89M 33.7M Sep/2025
Eli Lilly USD 26.54B 2.74B Dec/2025
Halozyme Therapeutics USD 48.81M 455.1M Dec/2025
Insmed USD 738.98M 206.6M Dec/2025
Karyopharm Therapeutics USD -269.26M 30.33M Sep/2025
MacroGenics USD 67M 20.38M Sep/2025
MannKind USD -44.55M 10.49M Sep/2025
Merck USD 51.85B 2.79B Sep/2025
Minerva Neurosciences USD -34.58M 2.47M Sep/2025
Novavax USD -156.67M 194.3M Sep/2025
Novo Nordisk DKK 26.56B 111.98B Jun/2025
Pfizer USD 92.8B 4.11B Sep/2025
Sanofi EUR 71.71B 1.55B Dec/2025
Xencor USD 635.59M 10.27M Dec/2025